TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

124 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    Molecular Signatures of Cutaneous Dupilumab Response

    Studying how dupilumab affects immune cells in eczema skin

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

    Testing the safety and how a drug works in people with Alzheimer’s

    📍 Clinical Trial Site · Montreal, · Get directions →

    The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    ✓ Study care freePhase 1Ages 40–80Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Lupus (SLE)Eczema / atopic dermatitis

    Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

    Testing whether baricitinib is safe in people with Job syndrome and lupus or eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones.

    ✓ Study care freePhase 1Ages 12–120Learn more →
  • Dementia / Alzheimer's

    Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

    Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia

    📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →

    The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

    ✓ Study care freePhase 2Ages 55–90Learn more →
  • Dementia / Alzheimer's

    Rifaximin SSD in Dementia Trial

    Testing a new form of rifaximin to change gut microbes in people with dementia

    📍 Richmond VA Medical Center · Richmond, VA · Get directions →

    Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

    ✓ Study care freePhase 1Ages 65+Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

    Testing a gene therapy in people with a genetic form of frontotemporal dementia

    📍 The Ohio State University (OSU) Wexner Medical Center · Columbus, OH · +2 more US sites · Get directions →

    The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer's

    SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

    Using brain scans to study how HIV affects the brain during treatment

    📍 Yale School of Medicne, Neuro ID Research Program · New Haven, CT · Get directions →

    The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Dementia / Alzheimer's

    Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer

    Testing an online program to help dementia caregivers share what they learn

    📍 Texas Christian University · Fort Worth, TX · +1 more US site · Get directions →

    The overarching goal of this work is to determine methods that improve caregiver education about the behavioral and psychological symptoms (BPSD) of dementia. The specific goal of this project is to extend our prior work to evaluate the impact of our educational intervention on caregivers' ability to transfer knowledge about the management of ADRD to real-world applied examples.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • Eczema / atopic dermatitis

    A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

    Testing whether a medicine called abrocitinib helps children with eczema and is safe

    📍 Cahaba Dermatology & Skin Health Center, LLC · Birmingham, AL · +9 more US sites · Get directions →

    This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks.

    ✓ Study care freePhase 3Ages 6–11Learn more →
  • Eczema / atopic dermatitis

    A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

    Testing BBT001 in healthy adults and adults with eczema

    📍 First OC Dermatology · Irvine, CA · +2 more US sites · Get directions →

    This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

    ✓ Study care freePhase 1Ages 18–72Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease

    📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    ✓ Study care freePhase 3Ages 60–85Learn more →
  • Eczema / atopic dermatitis

    Dupilumab De-escalation in Pediatric Atopic Dermatitis

    Testing whether stopping or lowering eczema treatment works for kids

    📍 Johns Hopkins Univerisity · Baltimore, MD · Get directions →

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    ✓ Study care freePhase 4Ages 1–17Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia

    📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Dementia / Alzheimer's

    Ferritin and Iron Burden in SAH sIRB

    Testing how iron and ferritin levels relate to brain injury after ruptured aneurysms with dementia

    📍 Univesity of Iowa Hospital and Clinics · Iowa City, IA · +1 more US site · Get directions →

    Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Dementia / Alzheimer's

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

    Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women

    📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →

    The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

    ✓ Study care freePhase 4Ages 60+WomenLearn more →
  • Dementia / Alzheimer's

    A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    Testing whether yearly donanemab helps people with dementia after a prior study

    📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →

    The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

    ✓ Study care freePhase 3Ages 55+Learn more →
  • Eczema / atopic dermatitis

    Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

    Testing a new drug dose in people with eczema and healthy volunteers

    📍 Clinical Site 101 · Fair Lawn, NJ · Get directions →

    This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARQ-234 in two populations: healthy volunteers and participants with moderate to severe atopic dermatitis (AD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Dementia / Alzheimer's

    A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    Testing a medicine in people with dementia to lower brain tau protein

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells.

    ✓ Study care freePhase 1Ages 21–80Learn more →
  • Dementia / Alzheimer's

    Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

    Testing a treatment called SNK01 in people with moderate Alzheimer’s disease

    📍 Behavioral Research Specialists, LLC · Glendale, CA · +6 more US sites · Get directions →

    The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 40–85Learn more →
  • Dementia / Alzheimer's

    A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

    Testing a drug called trontinemab for early Alzheimer’s disease dementia

    📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

    ✓ Study care freePhase 3Ages 50–90Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

    Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease

    📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →

    The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Eczema / atopic dermatitis

    Lebrikizumab in Moderate-to-severe Atopic Dermatitis

    Testing a medicine called lebrikizumab for long-term improvement in eczema

    📍 Physioseq USA - CA · Folsom, CA · +1 more US site · Get directions →

    This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    Testing how an imaging tracer works in people with memory loss and multiple sclerosis

    📍 Yale University PET Center · New Haven, CT · Get directions →

    The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Eczema / atopic dermatitis

    📍 Applied Research Center Of Arkansas /ID# 268547 · Little Rock, AR · +29 more US sites · Get directions →

    Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment.

    ✓ Study care freePhase 3Ages 2–11Learn more →
  • Dementia / Alzheimer's

    Epidemiology and Biomarker Study in Alzheimer's Disease

    Studying how memory changes over time and blood test results in people with dementia

    📍 Care Access - Houston · Houston, TX · Get directions →

    Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

    ✓ Study care freePhase 3Ages 55–75Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

    Testing how a new medicine works in healthy adults and early Alzheimer’s disease

    📍 Research Site 3 · East York, Ontario · Get directions →

    Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Eczema / atopic dermatitis

    The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

    Testing how Botox changes skin immune signals in people with eczema

    📍 University of Pittsburgh Medical Center · Pittsburgh, PA · +1 more US site · Get directions →

    The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    📍 Endeavor Health Systems · Evanston, IL · Get directions →

    CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.

    ✓ Study care freePhase 3Ages 45+Learn more →
  • Eczema / atopic dermatitis

    Ethnic Differences in Mechanisms of Action of Dupilumab

    Studying how a common eczema treatment works differently by race

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia

    📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    ✓ Study care freePhase 3Ages 60–85Learn more →
  • Eczema / atopic dermatitis

    A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

    Testing safety and effectiveness of a 1% eczema cream in babies and toddlers

    📍 AllerVie Clinical Research · Birmingham, AL · +36 more US sites · Get directions →

    The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.

    ✓ Study care freePhase 3Learn more →
  • Dementia / Alzheimer's

    TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

    Testing time-limited eating to see if it improves sleep and brain changes in early Alzheimer’s or

    📍 Shiley Marcos Alzheimer's Disease Center · San Diego, CA · Get directions →

    The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults.

    ✓ Study care freePhase 1Ages 60+Learn more →
  • Eczema / atopic dermatitis

    Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

    Testing the safety of LPX-TI641 and how the body handles it in eczema

    📍 Red River Research Partners · Fargo, ND · +1 more US site · Get directions →

    The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

    Comparing tau brain scan images in different types of dementia

    📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →

    The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Dementia / Alzheimer's

    A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    Testing the safety and effects of ACI-24.060 in Alzheimer’s and Down syndrome

    📍 Barrow Neurological Institute · Phoenix, AZ · +12 more US sites · Get directions →

    The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

    ✓ Study care freePhase 1Ages 35–85Learn more →
  • Dementia / Alzheimer's

    A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

    Testing a drug combination to treat agitation in adults with Alzheimer’s

    📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Eczema / atopic dermatitis

    FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

    Testing the safety of PF-07832837 in healthy people and eczema patients

    📍 Anaheim Clinical Trials, LLC · Anaheim, CA · +2 more US sites · Get directions →

    The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Eczema / atopic dermatitis

    A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

    Testing how a new medicine works and is tolerated in people with eczema

    📍 Sitryx Clinical Site · Arkansas City, AR · +5 more US sites · Get directions →

    The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Dementia / Alzheimer's

    Nicotinic Acid for the Treatment of Alzheimer's Disease

    Testing how well extended-release niacin reaches spinal fluid in dementia

    📍 IU Health Neuroscience Center · Indianapolis, IN · Get directions →

    Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid.

    ✓ Study care freePhase 1Ages 60–85Learn more →
  • Dementia / Alzheimer's

    A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    Testing whether a new drug is safe in people with early Alzheimer’s

    📍 K2 Medical Research, LLC · Maitland, FL · +5 more US sites · Get directions →

    The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.

    ✓ Study care freePhase 1Ages 50–85Learn more →
  • Dementia / Alzheimer's

    Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)

    Testing deep rTMS on a brain area for people with probable Alzheimer dementia to see if it is safe

    📍 UCLA TMS Clinical and Research Service · Los Angeles, CA · Get directions →

    The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects.

    ✓ Study care freePhase 1Ages 60–100Learn more →
  • Sickle cell disease

    A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

    Testing long-term treatment with a new medicine for sickle cell or thalassaemia

    📍 Univ of Alabama Birmingham · Birmingham, AL · +38 more US sites · Get directions →

    Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.

    ✓ Study care freePhase 3Ages 2+Learn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Eczema / atopic dermatitis

    📍 Leo Pharma Investigational site · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections \[SC\]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of assessments that rate the severity and extent of atopic dermatitis and its symptoms, as well as general health status and quality of life.

    ✓ Study care freePhase 3Ages 1–11Learn more →
  • Eczema / atopic dermatitis

    Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

    Testing an approach involving the skin microbiome to treat eczema

    📍 University of California, San Diego: Dermatology Clinical Trials Unit · San Diego, CA · +7 more US sites · Get directions →

    This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S.

    ✓ Study care freePhase 1Ages 6+Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

    Testing how safe escalating doses of fostamatinib are in people with stable sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Showing the first 60 of 124. Add filters or a location to narrow down.